HomeAI · summaries
Storia in 2 fonti
Nation's evolving role in global pharma enhanced
Samsung Epis Holdings has opened its first biopharmaceutical research and development center in China focused on antibody-drug conjugates, or ADCs, joining a growing list of multinational drugmakers deepening their presence in a country that has become one of the world's most active hubs for cancer drug innovation.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
global.chinadaily.com.cn
Nation's evolving role in global pharma enhanced
Samsung Epis Holdings has opened its first biopharmaceutical research and development center in China focused on antibody-drug conjugates, or ADCs, joining a growing list of…
- ·
koreaherald.com
[Bio USA] Samsung Biologics steps up CDMO tech race
SAN DIEGO — Samsung Biologics is accelerating research and development efforts to strengthen its position in the contract development and manufacturing organiza